According to Clarivate Epidemiology, there are approximately 4 million prevalent cases of Alzheimer’s disease (AD) and nearly 2.5 million prevalent cases of mild cognitive impairment (MCI) due to AD in the United States in 2022. Approved options are limited to only modestly effective procognitive symptomatic agents (e.g., donepezil, memantine) and Aduhelm (aducanumab), the first potential DMT for this debilitating disease whose launch has been met with considerable headwinds. Other anti-beta amyloid DMTs (Eisai / Biogen’s lecanemab, Eli Lilly’s donanemab, Roche’s gantenerumab) and several therapies for treating AD-associated psychosis (Acadia’s Nuplazid) and agitation (Lundbeck / Otsuka’s Rexulti, Avanir / Otsuka’s AVP-786, Axsome’s AXS-05, BioXcel’s BXCL-501) are advancing through late-phase development with near-term launch potential. As the AD therapy market enters a new era of treatment choice, understanding today’s treatment landscape and the patient journey is important for emerging players bringing novel brands to this large, underserved, and mostly generic market. Our Treatment Algorithms: Claims Data Analysis content provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Eisai, Novartis, AbbVie, AstraZeneca, Eli Lilly, Johnson & Johnson, Lundbeck / Otsuka, Acadia Pharmaceuticals.
Key drugs: Donepezil, galantamine, rivastigmine, rivastigmine patch, memantine IR, memantine XR, Namenda XR, Namzaric, antipsychotics, antidepressants.
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.